Compare Suzuken Co., Ltd. with Similar Stocks
Dashboard
1
With ROE of 9.20%, it has a very attractive valuation with a 0.89 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -17.02%, its profits have risen by 2.7% ; the PEG ratio of the company is 0.9
Stock DNA
Pharmaceuticals & Biotechnology
JPY 374,981 Million (Mid Cap)
10.00
NA
0.00%
-0.34
9.32%
0.90
Revenue and Profits:
Net Sales:
601,017 Million
(Quarterly Results - Mar 2026)
Net Profit:
7,123 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.94%
0%
-10.94%
6 Months
-24.55%
0%
-24.55%
1 Year
-17.45%
0%
-17.45%
2 Years
-5.59%
0%
-5.59%
3 Years
19.14%
0%
19.14%
4 Years
40.72%
0%
40.72%
5 Years
50.29%
0%
50.29%
Suzuken Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.77%
EBIT Growth (5y)
17.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
5.85
Tax Ratio
29.75%
Dividend Payout Ratio
18.33%
Pledged Shares
0
Institutional Holding
0.39%
ROCE (avg)
13.69%
ROE (avg)
5.93%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
0.89
EV to EBIT
4.12
EV to EBITDA
3.03
EV to Capital Employed
0.76
EV to Sales
0.06
PEG Ratio
0.91
Dividend Yield
NA
ROCE (Latest)
18.54%
ROE (Latest)
9.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Sep 2018
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
601,017.00
561,282.00
7.08%
Operating Profit (PBDIT) excl Other Income
12,330.00
10,479.00
17.66%
Interest
10.00
12.00
-16.67%
Exceptional Items
-969.00
-4,230.00
77.09%
Consolidate Net Profit
7,123.00
3,826.00
86.17%
Operating Profit Margin (Excl OI)
15.20%
13.10%
0.21%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 7.08% vs -1.90% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 86.17% vs 8.79% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
2,486,647.00
2,399,952.00
3.61%
Operating Profit (PBDIT) excl Other Income
48,727.00
49,189.00
-0.94%
Interest
42.00
41.00
2.44%
Exceptional Items
-872.00
-2,306.00
62.19%
Consolidate Net Profit
38,143.00
34,503.00
10.55%
Operating Profit Margin (Excl OI)
14.60%
15.50%
-0.09%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 3.61% vs 0.56% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 10.55% vs 18.98% in Mar 2025
About Suzuken Co., Ltd. 
Suzuken Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






